246
Participants
Start Date
November 21, 2018
Primary Completion Date
October 29, 2019
Study Completion Date
October 29, 2019
Insulin Degludec/Insulin Aspart
Patients will be treated with commercially available Insulin Degludec/Insulin Aspart (Ryzodeg®) in a pre-filled pen injector (FlexTouch®) according to routine clinical practice at the discretion of the treating physician in accordance with the Ryzodeg® label in Japan
Novo Nordisk Investigational Site, Arakawa-ku, Tokyo
Novo Nordisk Investigational Site, Chuo-ku, Tokyo
Novo Nordisk Investigational Site, Fukuoka-shi, Fukuoka
Novo Nordisk Investigational Site, Fukushima
Novo Nordisk Investigational Site, Higashiosaka-shi, Osaka
Novo Nordisk Investigational Site, Hokkaido
Novo Nordisk Investigational Site, Hosu-gun, Ishikawa
Novo Nordisk Investigational Site, Kanagawa
Novo Nordisk Investigational Site, Kanagawa
Novo Nordisk Investigational Site, Kawagoe-shi, Saitama
Novo Nordisk Investigational Site, Kawaguchi-shi, Saitama
Novo Nordisk Investigational Site, Kisarazu-shi, Chiba
Novo Nordisk Investigational Site, Kita-ku, Tokyo
Novo Nordisk Investigational Site, Nagano
Novo Nordisk Investigational Site, Saitama-shi, Saitama
Novo Nordisk Investigational Site, Sapporo-shi, Hokkaido
Novo Nordisk Investigational Site, Sendai-shi, Miyagi
Novo Nordisk Investigational Site, Shimotsuga-gun, Tochigi
Novo Nordisk Investigational Site, Shimotsuke-shi, Tochigi
Novo Nordisk Investigational Site, Shinjuku-ku, Tokyo
Novo Nordisk Investigational Site, Shizuoka-city, Shizuoka
Novo Nordisk Investigational Site, Shizuoka-shi, Shizuoka
Novo Nordisk Investigational Site, Shizuoka-shi, Shizuoka
Novo Nordisk Investigational Site, Tochigi
Novo Nordisk Investigational Site, Tokyo
Novo Nordisk Investigational Site, Tokyo
Novo Nordisk Investigational Site, Tsuchiura-shi,Ibaraki
Novo Nordisk Investigational Site, Yaizu-shi, Shizuoka
Novo Nordisk Investigational Site, Yokohama-shi, Kanagawa
Lead Sponsor
Novo Nordisk A/S
INDUSTRY